CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
复发/难治性多发性骨髓瘤仍然是一种具有挑战性的疾病，需要开发更有效的治疗选择。在过去十年中，随着新治疗模式的引入，骨髓瘤治疗取得了显著进展。这些新型疗法的主要新靶点之一是 B 细胞成熟抗原（BCMA），其表达于成熟 B 淋巴细胞和浆细胞上。目前可用的 BCMA 靶向治疗主要有三类，包括双特异性抗体（BsAbs）、抗体药物偶联物（ADCs）和嵌合抗原受体（CAR）T 细胞疗法。在这篇综述中，我们讨论了现有的 BCMA 靶向治疗，并对当前可用的治疗和未来发展提供了见解，特别关注临床疗效和常见的药物相关不良事件。
Relapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these novel therapeutics has been B-cell maturation antigen (BCMA), which is expressed on mature B-lymphocytes and plasma cells.
There are three main categories of BCMA-targeted therapies currently available, including bispecific antibodies (BsAbs), antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. In this review, we discuss the existing BCMA-targeted therapies and provide insights into currently available treatment and future developments, with a particular focus on clinical efficacy and common drug-related adverse events.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
